Cichocki, Frank http://orcid.org/0000-0003-3043-0653
Bjordahl, Ryan
Goodridge, Jodie P.
Mahmood, Sajid
Gaidarova, Svetlana
Abujarour, Ramzey
Davis, Zachary B.
Merino, Aimee http://orcid.org/0000-0003-4433-0127
Tuininga, Katie
Wang, Hongbo
Kumar, Akhilesh
Groff, Brian
Witty, Alec
Bonello, Greg
Huffman, Janel
Dailey, Thomas
Lee, Tom T.
Malmberg, Karl-Johan http://orcid.org/0000-0002-8718-9373
Walcheck, Bruce
Höpken, Uta http://orcid.org/0000-0002-0776-4893
Rehm, Armin http://orcid.org/0000-0001-7490-1950
Valamehr, Bahram http://orcid.org/0000-0002-5917-3585
Miller, Jeffrey S. http://orcid.org/0000-0002-0339-4944
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL155150)
Center for Strategic Scientific Initiatives, National Cancer Institute (CA111412, CA65493, CA197292)
Article History
Received: 23 February 2022
Accepted: 20 November 2022
First Online: 29 November 2022
Competing interests
: F.C., K.J.M., and J.S.M. are paid consultants for Fate Therapeutics, and they receive research funds and stock options from this relationship. B.W. receives research funds from Fate Therapeutics. J.S.M. serves on the Scientific Advisory Boards of ONK Therapeutics and Wugan, and is a paid consultant for Vycellix and GT BioPharma (with research funds and stock options) all unrelated to the content of this manuscript. R.B., J.P.L., S.M., S.G., R.A., B.G., A.W., G.B., J.H., T.D., T.T.L., and B.V. are employees of Fate Therapeutics. The remaining authors declare no competing interests. Fate Therapeutics owns patents (METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION; Patent No. 10,626,372) covering the iNK cells reported here.